IMGN News and Press, ImmunoGen Inc. From 07/28/23

2023-07-28 11:55:37 ET ImmunoGen ( NASDAQ: IMGN ) is scheduled to announce Q2 earnings results on Monday, July 31st, before market open. The consensus EPS Estimate is -$0.15 (+37.5% Y/Y) and the consensus Revenue Estimate is $46.6M (+228.2% Y/Y). Over the last 2 years,...

2023-07-28 09:55:21 ET Major earnings expected before the bell on Monday include: Alliance Resource Partners ( ARLP ) ImmunoGen ( IMGN ) ON Semiconductor ( ON ) Oxford Lane Capital ( OXLC ) SoFi Technologies ( SOFI ) For further details see: ...

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will participate in a fireside chat at the upcoming Canaccord Genuity 43 rd Annual Growth Conference in Boston, MA. The presentati...

Collaboration Combines ImmunoGen's Proprietary Linker-Payload Technology with Antibodies Developed by ImmunoBiochem Agreement Grants ImmunoGen an Exclusive License to Existing Antibodies Generated by ImmunoBiochem and an Option to Expand Partnership to Incorporate Additional Targets ...

2023-07-22 03:21:52 ET Summary Mersana Therapeutics' stock price has had a turbulent year, with shares soaring over 100% before plummeting by 60% due to failure to demonstrate clinical benefits in ongoing studies. The recent clinical hold and Grade 5 bleeding events raised serious...

2023-07-18 12:35:34 ET Summary ELAHERE only has accelerated approval from the FDA; the confirmatory trial was positive. The company's lead product seems to have nowhere near the insurance coverage that management claims. However, the antibody-drug conjugate is better than chem...

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Monday, July 31, 2023 to discuss its second quarter 2023 operating results. Management w...

2023-07-06 21:31:50 ET Summary ImmunoGen's Q1 2023 revenue increased to $49.9 million, primarily due to sales of Elahere and an upfront fee from Vertex Pharmaceuticals. The company plans to close a $325 million public offering. The MIRASOL trial confirmed Elahere's potential as a ...

2023-06-27 07:00:00 ET Summary With the cost of living has increased dramatically, we're all seeking ways to increase our income. Getting double-digit yields with high-yield stocks is a risky proposition. However, exploiting human nature, we can safely generate higher yields w...

2023-06-23 11:12:16 ET As Wall Street approaches the midpoint of 2023, many mid-cap stocks have provided investors with sizable returns. Of the roughly 1,000 mid-cap stocks available for investors, 101 of them have returned 50% or more since the end of 2022. This includes several ralli...